Cephalon (CEPH) is in a position most drug companies would envy. The company is about to launch four new compounds, effectively doubling its portfolio of US products. The Pennsylvania biotechnology company is waiting for regulatory approval for new drugs to treat excessive sleepiness, ADHD, cancer, pain, and alcohol dependence….
